Partnerships Archives

News and Trends 21 Apr 2023

RetinAI and Boehringer Ingelheim to use AI to develop treatment for geographic atrophy

RetinAI Medical AG, which creates clinical and imaging data management software and advanced analytics using artificial intelligence (AI) for ophthalmology, is partnering with Boehringer Ingelheim. The companies aim to improve patient outcomes in geographic atrophy (GA) by combining RetinAI’s Discovery platform and AI tools with Boehringer Ingelheim’s research in retinal diseases. GA is a progressive, […]

April 21, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 4 Apr 2023

BioNTech adds antibody-drug conjugates to cancer portfolio with potential $1.5B partnership deal

BioNTech SE and Duality Biologics (Suzhou) Co. Ltd. have entered into exclusive license and collaboration agreements for two antibody-drug conjugate (ADC) assets to develop, manufacture and commercialize the two assets globally, excluding mainland China, Hong Kong Special Administrative Region and Macau Special Administrative Region. With this collaboration, ADCs will become an additional drug class in […]

April 4, 2023 - 3 minutesmins - By Jim Cornall

BIO-Europe Spring 2023: The Highlights

BIO-Europe Spring is one of Europe’s biggest biotech partnering events with discussion topics ranging from platform technologies and manufacturing to biotech investments. Here are some of the key take-home reports from the proceedings. The event, which took place from March 20 to 22, in the budding biotech hub of Basel, Switzerland, was in full swing […]

April 3, 2023 - 28 minutesmins - By External Contributor

In Depth 31 Mar 2023

How has the collapse of the Silicon Valley Bank affected the biotech industry?

When investors got wind of Silicon Valley Bank (SVB) being forced to sell its treasury bonds at a loss, owing in part to surging interest rates in the past year – a move by the Federal Reserve to counteract rising inflation – panic followed a bank run. And in a swift spur of events, the […]

March 31, 2023 - 8 minutesmins - By Roohi Mariam Peter

Opinion 24 Mar 2023

PAN-TB regimens to address growing TB drug resistance

By Dr. Charles Wells, head of therapeutics development at Gates Medical Research Institute As nearly one-quarter of the world’s population is presumed to be infected with Mycobacterium tuberculosis bacteria and are at risk for developing active tuberculosis (TB), the disease represents a major public health challenge globally. As reported by the World Health Organization (WHO), […]

March 24, 2023 - 5 minutesmins - By External Contributor

News and Trends 23 Mar 2023

OncoC4 and BioNTech partner in the commercialization of cancer drug candidate

German biopharma BioNTech has closed a licensing deal with the U.S.-based clinical-stage company OncoC4 for the development and commercialization of the latter’s lead candidate ONC-392, for the treatment of cancer. OncoC4 will receive $200 million upfront, and the transaction is expected to be completed in the first half of 2023. The company will also be […]

March 23, 2023 - 2 minutesmins - By Roohi Mariam Peter

Expert Advice 20 Mar 2023

Nine tips to succeed in pharma-biotech partnerships

The question of whether to partner with another company is critical to the long-term development of a biotech. Nonetheless, it can be easy for a small company to underestimate the resources it needs to put into a successful collaboration. Here, we’ll go over some expert advice on what to do and what not to do […]

March 20, 2023 - 9 minutesmins - By Alexander Burik

Expert Advice 14 Mar 2023

5 reasons why collaboration is important in research

In the life sciences industry, collaboration is paramount in the field of research, to help move ideas and programs forward through the various stages. Here, experts explain the importance of research collaboration for biotechs. Collaboration in research is critical for the long-term success of biotechs, and going it alone is rarely a feasible option, particularly […]

March 14, 2023 - 7 minutesmins - By Willow Shah-Neville

News and Trends 13 Mar 2023

Sanofi adds diabetes drug through Provention Bio $2.9B acquisition

Sanofi and Provention Bio, Inc., a U.S.-based, publicly traded biopharmaceutical company focused on intercepting and preventing immune-mediated diseases including type 1 diabetes (T1D), have entered into an agreement under which Sanofi has agreed to acquire Provention Bio, Inc., for $25.00 per share in cash, representing an equity value of approximately $2.9 billion. The transaction adds […]

March 13, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 8 Mar 2023

Affibody and Chiesi Group to develop treatments for respiratory diseases

Affibody AB and Chiesi Farmaceutici S.p.A have announced a collaboration and licensing agreement to develop and commercialize innovative treatments for respiratory diseases using Affibody’s proprietary technology. Under the terms of the agreement, the parties will collaborate to progress up to three programs based on Affibody molecules against undisclosed targets for respiratory diseases. Chiesi will fund […]

March 8, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 3 Mar 2023

Lilly to develop Confo pain drug

Confo Therapeutics, which works on the discovery of medicines targeting G-protein coupled receptors (GPCRs), has announced a worldwide licensing agreement with Eli Lilly and Company for Confo’s clinical stage CFTX-1554 and back-up compounds. CFTX-1554, a novel inhibitor of the angiotensin II type 2 receptor (AT2R) is currently in phase 1 clinical development. It represents a […]

March 3, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 3 Mar 2023

Porton and DanausGT look to boost development of gene and cell therapy

Porton Advanced Solutions Ltd. and DanausGT Biotechnology Co., Ltd. have announced a strategic collaboration in gene and cell therapy pipelines to expedite the development of innovative therapeutics. As an end-to-end gene and cell therapy service provider, Porton Advanced CDMO offers solutions covering plasmids, cell therapy, gene therapy, oncolytic viruses, mRNA therapy, and bacterial therapy. DanausGT […]

March 3, 2023 - 3 minutesmins - By Jim Cornall

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us